Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Revenues down 4% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
 
1Q Revenues: $10.3 billion (-4%)

1Q Earnings: $1.7 billion (+7%)

Comments: Pharmaceutical sales were down 5% to $8.5 billion, including a 2% negative impact from foreign exchange, and loss of market exclusivity for products, including TEMODAR (-62%), NASONEX and SINGULAIR (-19% and 20%, respectively) and COZAAR (-23%). Combined sales of ZETIA and VYTORIN decreased 5% to $972 million, driven by lower demand in the U.S. Combined sales of REMICADE and SIMPONI were up 16% to $760 million in the quarter. ISENTRESS sales were up 8% to $390 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters